business
FDA warns Maple Grove drug company
- Article by: JANET MOORE , Star Tribune
- Updated: August 16, 2010 - 8:24 PM
Upsher-Smith Laboratories didn't do enough studies on midodrine hydrochloride or ProAmatine, a low-blood-pressure drug, the FDA claims.
- 6
- comments
resize text 
- buy reprints
The Food and Drug Administration has proposed pulling from the market a low-blood-pressure drug that is made by several drug companies, including Maple Grove-based Upsher-Smith Laboratories.
The drug, called midodrine hydrochloride or ProAmatine, was approved by federal regulators on an accelerated basis in 1996 because it was seen as a treatment for "serious or life-threatening diseases."
A caveat of fast-track approval was that both the original and generic manufacturers would conduct additional clinical trials to verify the drug's clinical benefit. The FDA maintains those additional tests on humans have not been done by the drug's original or generic manufacturers. The drug is marketed by Shire Development Inc., and as a generic by Apotex Corp., Impax Laboratories, Mylan Pharmaceuticals, Sandoz Inc., and Upsher-Smith.
The drug is intended to treat orthostatic hypotension, a condition in which patients are unable to maintain blood pressure while in an upright position, leading to dizziness and fainting.
Last year, about 100,000 people in the United States filled prescriptions for the drug, according to the FDA.
"We've worked continuously with the drug companies to obtain additional data showing the drug's clinical benefits to patients," Dr. Norman Stockbridge, director of the FDA's Cardiovascular and Renal Drugs division, said. "Since the companies have not been able to provide evidence to confirm the drug's benefit, the FDA is pursuing a withdrawal of the product."
This is the first time the FDA has asked for a drug to be removed from the market for failure to conduct the required follow-up study. Last year, the Government Accountability Office cited ProAmatine as an example of FDA's failure to track certain drugs after launch.
The FDA advises patients who are taking the drug to keep doing so, but to consult with their physician about treatment options. Agency spokeswoman Sandy Walsh said Monday's announcement isn't about the safety of the drug. "The FDA has conducted routine adverse-event monitoring over the years and there are no significant adverse events to report."
Founded by a pharmacist in 1919, Upsher-Smith originally marketed a drug to treat congestive heart failure. The company has since expanded into dermatology, women's health, as well as neurology products treating epilepsy and Parkinson's disease.
The firm has 30 days to submit written comments. If the FDA continues to believe that withdrawal is warranted, approval of all products, including generic, will be withdrawn.
The company couldn't be reached for comment Monday.
Janet Moore • 612-673-7752
- 6
- comments
- resize text
- buy reprints
ADVERTISEMENT
- Lew taps government retiree pension fund
- Twin Cities market for office buildings picks up
- Minnesota to get stricter law on home foreclosures
- Demand is soaring for Apple’s first product
- China sees wider role for private business
- Oil estimates double: 7.4 billion barrels in N.D. and Montana
- Downtown East in Minneapolis poised for second chance
- Medtronic sheds 2,000 jobs worldwide, 500 in Minnesota
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
inside the StarTribune
-
425 Portland Av. S.
Minneapolis, MN 55488
(612) 673-4000
- Company
- Subscriber Services
- Website
- Buy Ads
- Store
- Connect with Us
© 2013 StarTribune. All rights reserved.
StarTribune.com is powered by Limelight Networks
Newspaper Subscriptions
eEdition
RSS
Newsletters